Story perspectives

Hepatocyte mRNA Silencing Triples T-Cells, Cuts Tumors 50%

5/7/2026

Summary

Icahn Researchers Identify

On April 29, 2026, Icahn School of Medicine researchers reported that non-immune cells, not dendritic cells, determine mRNA vaccine effectiveness.
Silencing mRNA in muscle lowered T-cell responses.
Silencing mRNA in hepatocytes tripled T-cell responses, reduced hepatocyte death, and improved safety for gene-editing and CAR-T therapies.
An mRNA vaccine avoiding hepatocyte expression cut tumor burden by over 50 % in a mouse lymphoma model by boosting killer T cells.

Summary

FDA Reviews Flu

The FDA will rule on Moderna’s mRNA flu vaccine by August 5, 2026.
The agency dismissed the original filing with a standard comparator.
It now reviews an amended application that splits approval for ages 50-64 and 65+.
Health Secretary Robert F. Kennedy Jr. called mRNA Covid vaccines “the deadliest” and cancelled nearly $500 million in funding.
Moderna withdrew its application after the FDA’s data request, despite the European Commission’s April approval of the flu-COVID mRNA vaccine.

1 of 2

Icahn Researchers Identify

On April 29, 2026, Icahn School of Medicine researchers reported that non-immune cells, not dendritic cells, determine mRNA vaccine effectiveness.
Silencing mRNA in muscle lowered T-cell responses.
Silencing mRNA in hepatocytes tripled T-cell responses, reduced hepatocyte death, and improved safety for gene-editing and CAR-T therapies.
An mRNA vaccine avoiding hepatocyte expression cut tumor burden by over 50 % in a mouse lymphoma model by boosting killer T cells.

1 / 2